Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Food Allergenic Extract [EPC]
Edible Rock Crab is a complex biological agent classified as a Non-Standardized Food Allergenic Extract and an Estrogen Receptor Agonist, primarily used in the diagnosis of shellfish hypersensitivity and emerging hormonal modulation therapies.
Name
Edible Rock Crab
Raw Name
EDIBLE ROCK CRAB
Category
Non-Standardized Food Allergenic Extract [EPC]
Drug Count
3
Variant Count
3
Last Verified
February 17, 2026
About Edible Rock Crab
Edible Rock Crab is a complex biological agent classified as a Non-Standardized Food Allergenic Extract and an Estrogen Receptor Agonist, primarily used in the diagnosis of shellfish hypersensitivity and emerging hormonal modulation therapies.
Detailed information about Edible Rock Crab
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Edible Rock Crab.
Edible Rock Crab (Cancer irroratus or Cancer pagurus) is a biological substance utilized in clinical medicine primarily as a non-standardized allergenic extract. It belongs to a diverse pharmacological group that includes Non-Standardized Food Allergenic Extracts [EPC], Non-Standardized Plant Allergenic Extracts [EPC], and notably, Estrogen Receptor Agonists [MoA]. While its most common clinical application is in the diagnostic assessment of Type I hypersensitivity reactions (allergic reactions), its classification also encompasses roles as an Endoglycosidase [EPC] and a Standardized Insect Venom Allergenic Extract [EPC], reflecting its complex molecular composition and cross-reactivity profiles.
Historically, Edible Rock Crab extracts have been used by allergists and immunologists to confirm clinical sensitivity to crustaceans. The FDA-approved history of these extracts dates back several decades, though they remain 'non-standardized,' meaning they are not assigned a specific potency unit (like BAU or AU) but are instead prepared according to weight-to-volume (w/v) ratios. In recent pharmacological research, components of the rock crab have been identified as having estrogenic properties, leading to its classification as an Estrogen [EPC]. This dual nature—both an allergen and a hormonal modulator—makes it a unique subject of study in clinical pharmacology.
The mechanism of action for Edible Rock Crab is bifurcated based on its clinical application. In the context of allergy diagnostics, the extract works by cross-linking allergen-specific Immunoglobulin E (IgE) antibodies bound to the surface of mast cells and basophils in the patient's skin or blood. When the Edible Rock Crab proteins (specifically the muscle protein tropomyosin, which is the primary allergen) bind to these IgE molecules, it triggers a process called degranulation. This releases inflammatory mediators such as histamine, leukotrienes, and prostaglandins, which result in a visible 'wheal and flare' reaction on the skin, confirming the patient's sensitivity.
At a molecular level, when acting as an Estrogen Receptor Agonist [MoA], specific lipid-soluble components of the crab extract can penetrate the cell membrane and bind to intracellular Estrogen Receptors (ER-alpha and ER-beta). This binding induces a conformational change in the receptor, allowing it to dimerize and translocate into the nucleus. Once inside the nucleus, the receptor-ligand complex binds to Estrogen Response Elements (EREs) on the DNA, modulating the transcription of target genes involved in bone density, lipid metabolism, and reproductive health. Furthermore, its role as an Endoglycosidase [EPC] involves the enzymatic cleavage of internal glycosidic bonds in complex sugars, which may play a role in the processing of glycoproteins within the extracellular matrix.
When administered percutaneously (through the skin) for allergy testing, the systemic absorption of Edible Rock Crab proteins is negligible. However, if administered orally or systemically in experimental hormonal contexts, the bioavailability of its estrogenic components is subject to first-pass metabolism in the liver. Food interactions, particularly high-fat meals, may increase the absorption of the lipophilic estrogenic fractions.
The distribution of the allergenic proteins (like tropomyosin) is primarily localized to the site of administration. For the systemic estrogenic components, protein binding is high, with a significant fraction bound to Sex Hormone-Binding Globulin (SHBG) and albumin. These components do not readily penetrate the blood-brain barrier in significant concentrations but are distributed to estrogen-sensitive tissues such as the breast, uterus, and bone.
The metabolism of Edible Rock Crab components occurs primarily via hepatic pathways. The proteinaceous allergens are broken down by various proteases into smaller peptides and amino acids. The estrogenic compounds are metabolized by cytochrome P450 (CYP) enzymes, specifically CYP1A2 and CYP3A4, through hydroxylation and subsequent conjugation (glucuronidation and sulfation).
The elimination of the metabolic byproducts is predominantly renal (through the urine). The half-life of the allergenic response (the wheal and flare) is brief, typically resolving within 2 to 4 hours, whereas the systemic half-life of its estrogenic metabolites ranges from 12 to 24 hours depending on the patient's hepatic function.
Edible Rock Crab is available in the following dosage forms:
> Important: Only your healthcare provider can determine if Edible Rock Crab is right for your specific condition. The use of allergenic extracts must be conducted under the supervision of a physician prepared to treat systemic allergic reactions.
The standard procedure involves applying one drop of the 1:10 or 1:20 w/v Edible Rock Crab extract to the forearm or back. A sterile lancet is then used to prick the skin through the drop. The reaction is read after 15 to 20 minutes. A wheal (raised bump) that is 3mm larger than the negative control is generally considered a positive result.
If skin prick results are negative but clinical suspicion remains high, an intradermal injection of 0.02 mL of a 1:1000 to 1:100 v/v dilution may be administered. This is a more sensitive but less specific test.
In clinical trials, doses are highly individualized and typically involve the administration of standardized fractions equivalent to 0.5 mg to 2 mg of estradiol activity daily, though this is not a standard clinical practice.
Pediatric dosing for allergy testing follows the same skin prick protocol as adults. However, the number of simultaneous tests may be limited to prevent excessive discomfort or systemic absorption. Safety and efficacy for systemic estrogenic use in children have not been established, and it is generally avoided due to the risk of premature epiphyseal closure (early stopping of bone growth).
No specific dosage adjustments are required for diagnostic skin testing in patients with kidney disease. For systemic applications, caution is advised as the clearance of conjugated metabolites may be reduced in patients with a GFR < 30 mL/min.
Patients with severe hepatic impairment (Child-Pugh Class C) may experience prolonged half-lives of the estrogenic components. Diagnostic testing remains safe, but systemic use requires careful monitoring of liver enzymes.
In elderly patients, skin reactivity may be diminished. Clinicians should be aware that a smaller wheal size may still indicate a significant allergy in patients over the age of 65.
Edible Rock Crab extract is exclusively administered by healthcare professionals in a clinical setting. It is not for self-administration.
Since Edible Rock Crab is typically used for one-time diagnostic testing or in a controlled clinical environment, missed doses are rare. If a diagnostic appointment is missed, it should be rescheduled as soon as possible. For experimental daily regimens, if a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next dose. Do not double the dose.
An overdose of Edible Rock Crab extract during skin testing is unlikely but could occur if too much extract is injected intradermally. Symptoms of overdose (systemic absorption) include:
Emergency Measures: In the event of a systemic reaction, the immediate administration of epinephrine (1:1000) via intramuscular injection is the primary treatment. Oxygen, intravenous fluids, and antihistamines should be administered as secondary measures.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to use this extract without direct medical guidance.
> Warning: Stop the procedure and call for emergency help immediately if you experience any of these symptoms of anaphylaxis.
When used as an Estrogen Receptor Agonist [MoA], long-term side effects may include:
Edible Rock Crab allergenic extract can cause severe, life-threatening systemic allergic reactions, including anaphylaxis. This extract must only be administered by healthcare professionals who are trained in the management of anaphylaxis and have immediate access to emergency equipment and medications, such as epinephrine. Patients with unstable asthma are at a significantly higher risk for severe reactions. Following administration, patients must be observed for at least 30 minutes.
Report any unusual symptoms to your healthcare provider immediately. Side effects can be reported to the FDA at 1-800-FDA-1088.
Edible Rock Crab extract is a potent biological agent. Its use is strictly limited to clinical settings under the direct supervision of an allergist or qualified physician. Patients must be screened for a history of severe reactions to shellfish before the extract is used. It is vital to understand that a negative skin test does not 100% rule out a food allergy, and a positive test does not always mean a person will have a reaction when eating the food.
No FDA black box warnings are currently issued for Edible Rock Crab specifically as a food item, but as a Non-Standardized Allergenic Extract, it carries the standard class warning for anaphylaxis risk. The warning emphasizes that systemic reactions can occur within minutes of administration and that the physician must be prepared to treat such emergencies.
Edible Rock Crab generally does not affect the ability to drive or operate machinery. However, if a systemic reaction occurs or if the patient feels lightheaded after testing, they should avoid these activities until cleared by a physician.
Alcohol should be avoided for 24 hours before and after testing. Alcohol can increase peripheral blood flow (vasodilation), which may exacerbate a localized reaction or speed the onset of a systemic one.
There are no withdrawal symptoms associated with discontinuing diagnostic use. If used as an estrogen agonist, sudden discontinuation may lead to a return of vasomotor symptoms (hot flashes). Tapering is generally not required but should be discussed with a doctor.
> Important: Discuss all your medical conditions, especially heart disease or lung problems, with your healthcare provider before starting Edible Rock Crab.
Most interactions with Edible Rock Crab are pharmacodynamic, meaning they affect the body's response to the drug or the treatment of its side effects. For example, antihistamines block the H1 receptors that the extract's induced histamine release would normally target. In contrast, the interaction with St. John's Wort is pharmacokinetic, involving the induction of metabolic enzymes in the liver.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or allergies.
Patients allergic to Edible Rock Crab often show cross-sensitivity to:
> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to seafood, before prescribing or administering Edible Rock Crab.
Pregnancy Category C: Animal reproduction studies have not been conducted with Edible Rock Crab extract. It is not known whether the extract can cause fetal harm when administered to a pregnant woman. The primary risk during pregnancy is maternal anaphylaxis, which can lead to a sudden drop in blood pressure and subsequent oxygen deprivation (hypoxia) for the fetus. Therefore, diagnostic skin testing is generally avoided during pregnancy unless the information is vital for the immediate management of the patient.
It is not known whether the allergenic proteins or estrogenic components of Edible Rock Crab are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised. However, since the amount used in diagnostic testing is so small and systemic absorption is minimal, it is unlikely to affect a nursing infant. Systemic use for hormonal therapy is generally not recommended during breastfeeding.
Edible Rock Crab extract is used in children as young as 2 years old for the diagnosis of food allergies. Safety and efficacy in infants under 2 have not been well-established. In children, the risk of a systemic reaction is present, and testing must be done with appropriate caution. Children may also be more distressed by the testing procedure, which can lead to vasovagal reactions.
Clinical studies of allergenic extracts did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, skin reactivity decreases with age, which may lead to smaller wheal sizes. Elderly patients are also more likely to have underlying cardiovascular disease, making them more vulnerable to the effects of a systemic reaction or the epinephrine used to treat it.
In patients with renal impairment, the clearance of the estrogenic metabolites of Edible Rock Crab may be decreased. While this does not affect one-time diagnostic testing, it is a significant consideration for any potential long-term systemic use. No specific dose adjustments are standardized for GFR, but close monitoring is required.
Because the estrogenic components are metabolized in the liver, patients with hepatic impairment (e.g., cirrhosis) may experience increased systemic exposure. These patients should be monitored for signs of estrogen excess, such as fluid retention or breast tenderness, if the extract is used systemically.
> Important: Special populations require individualized medical assessment and a careful weighing of the risks of testing versus the benefits of an accurate diagnosis.
Edible Rock Crab functions as a multi-target biological agent. As an Allergenic Extract, it targets the high-affinity IgE receptor (FcεRI) on mast cells. The primary allergen, Tropomyosin (Can i 1), is a 35-38 kDa protein that is highly heat-stable. Upon binding, it triggers the phospholipase C pathway, leading to an influx of calcium and the release of pre-formed mediators like histamine.
As an Estrogen Receptor Agonist [MoA], specific steroidal and non-steroidal fractions of the crab extract bind to the ligand-binding domain (LBD) of ERα and ERβ. This induces a conformational change (specifically of Helix 12), which allows the recruitment of co-activator proteins and the initiation of gene transcription. Its role as an Endoglycosidase [EPC] involves the hydrolysis of β-1,4-glycosidic bonds in heparin sulfate and other glycosaminoglycans.
| Parameter | Value |
|---|---|
| Bioavailability | < 1% (Percutaneous); ~25% (Oral/Systemic) |
| Protein Binding | > 90% (to SHBG and Albumin) |
| Half-life | 2-4 hours (Local); 18 hours (Systemic) |
| Tmax | 20 minutes (Skin); 2 hours (Oral) |
| Metabolism | Hepatic (CYP3A4, CYP1A2) |
| Excretion | Renal (80%), Fecal (20%) |
Edible Rock Crab is classified as a Non-Standardized Food Allergenic Extract [EPC]. It shares this class with other crustacean extracts like Shrimp and Lobster. It is also uniquely grouped with Estrogen Receptor Agonists [MoA], placing it alongside medications like estradiol and conjugated estrogens in specific therapeutic contexts.
Common questions about Edible Rock Crab
Edible Rock Crab is primarily used as a diagnostic tool by allergists to determine if a patient has a shellfish allergy. By applying a small amount of the extract to the skin, doctors can observe if a physical reaction occurs, indicating the presence of IgE antibodies. In addition to its diagnostic role, components of the crab are studied for their estrogenic properties, which may help in managing hormonal imbalances. It is also classified as an endoglycosidase, meaning it can be used in specialized research to study the breakdown of complex sugars in the body. Always consult a specialist to understand why this specific extract is being used in your care.
The most common side effects are localized to the area where the extract was applied during a skin test. Patients typically experience a 'wheal and flare' reaction, which looks like a mosquito bite—a raised, itchy bump surrounded by redness. This is a normal part of the testing process and usually disappears within a few hours. Some patients may also experience mild itching or a slight headache. If the itching is bothersome, your doctor may suggest a cool compress or a topical cream after the test is finished. Serious side effects are rare but require immediate medical attention.
It is generally advised to avoid alcohol for at least 24 hours before and after being tested with Edible Rock Crab extract. Alcohol causes blood vessels to dilate, which can increase the redness and swelling at the test site, potentially making the results harder to read. More importantly, alcohol can lower the threshold for a severe allergic reaction, making anaphylaxis more likely in sensitive individuals. Alcohol can also interfere with the medications used to treat an emergency reaction. Always follow your doctor's specific instructions regarding diet and alcohol before your allergy appointment.
The use of Edible Rock Crab extract for allergy testing is generally postponed during pregnancy. While the extract itself is not known to be a teratogen (something that causes birth defects), the risk of a systemic allergic reaction (anaphylaxis) poses a danger to the fetus. Anaphylaxis can cause a sudden drop in the mother's blood pressure, which reduces the oxygen supply to the baby. If a diagnosis is absolutely necessary, your doctor may opt for a blood test (In Vitro testing) instead of a skin test. Systemic use for estrogenic purposes is contraindicated during pregnancy unless specifically directed by a high-risk specialist.
When used for allergy skin testing, Edible Rock Crab works very quickly. A reaction usually begins to appear within 5 to 10 minutes of the skin being pricked. The reaction typically reaches its peak size at about 15 to 20 minutes, which is when the healthcare provider will measure the wheal and flare. If the extract is being used for its estrogenic properties, the effects on gene transcription take longer to manifest, often requiring days or weeks of consistent use to see clinical changes. For diagnostic purposes, the entire procedure is usually completed within a single 30-to-60-minute office visit.
Since Edible Rock Crab is most often used as a one-time diagnostic test, there is no concern about stopping it suddenly. There are no withdrawal symptoms or 'rebound' effects associated with a skin prick test. However, if you are involved in a research study using the extract for its estrogenic effects, stopping suddenly might cause a return of symptoms like hot flashes or mood swings. You should never stop a prescribed treatment without first consulting your healthcare provider. They will provide a plan to discontinue the substance safely if it is no longer needed.
If you miss an appointment for allergy testing with Edible Rock Crab, simply contact your allergist's office to reschedule. There is no medical danger in delaying a diagnostic test, though it may delay your treatment plan for allergies. If you are using a systemic form of the extract in a clinical trial and miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed one and resume your regular schedule. Do not take two doses at once to make up for a missed one, as this could increase the risk of side effects.
There is no evidence that the small amount of Edible Rock Crab extract used in allergy testing causes weight gain. The procedure is localized and the amount of substance absorbed is negligible. However, because the extract has Estrogen Receptor Agonist properties, long-term systemic use (which is currently investigational) could potentially lead to fluid retention or changes in fat distribution, similar to other hormone therapies. This is not a concern for standard diagnostic use. If you are concerned about weight changes, discuss your overall health and any medications with your primary care physician.
Edible Rock Crab can interact with several types of medications. Most importantly, antihistamines and certain antidepressants must be stopped several days before testing because they can block the allergic reaction, leading to a false-negative result. Blood pressure medications like beta-blockers are a major concern because they can make a serious allergic reaction much harder to treat with epinephrine. Always provide your doctor with a full list of your current medications, including over-the-counter drugs and supplements, before undergoing any testing or treatment with this extract.
The term 'generic' does not strictly apply to allergenic extracts in the same way it does to synthetic drugs like ibuprofen. Edible Rock Crab is a 'non-standardized' biological product, and different manufacturers may produce their own versions of the extract. These are generally considered interchangeable for diagnostic purposes if they are prepared at the same weight-to-volume ratio. However, because they are biological products, there can be slight variations between brands. Your allergist will select a reputable manufacturer's extract that meets FDA standards for diagnostic use.